Strategic Science & Technologies, LLC
Strategic Science & Technologies, LLC (SST) is a Cambridge, MA-based, privately funded, clinical stage biotechnology company specializing in innovative topical drug delivery technologies. The company's patented KNOSIS technology enables targeted local delivery of active pharmaceutical ingredients, advancing multiple programs into clinical trials. SST focuses on developing first-in-class topical treatments for conditions such as Female Sexual Arousal Disorder (FSAD) and Erectile Dysfunction (ED), with a strategic approach to accelerate development and commercialization through FDA 505(b)(2) regulatory pathways. SST collaborates with leading experts in sexual health and medicine and seeks partnerships for its clinical programs.
Industries
Nr. of Employees
small (1-50)
Strategic Science & Technologies, LLC
Patents
Products
Topical sildenafil cream (3.6%) — prescription candidate for female sexual arousal disorder (FSAD)
Topical cream formulation of sildenafil developed to increase genital blood flow and provide a local therapeutic effect; completed Phase 1 PK/safety and progressed into Phase 2/Phase 2b clinical development.
Topical sildenafil cream (3.6%) — OTC candidate for erectile dysfunction (ED)
Topical cream formulation of sildenafil developed for local treatment of erectile dysfunction with the goal of low systemic exposure and potential OTC accessibility.
Topical ibuprofen cream (7.5%) — OTC candidate for localized pain
Topical ibuprofen cream formulated to deliver therapeutic analgesic levels to inflamed tissue while maintaining low systemic plasma concentrations; completed Phase 1 PK/safety and Phase 2 trials.
Topical sildenafil cream (3.6%) — prescription candidate for female sexual arousal disorder (FSAD)
Topical cream formulation of sildenafil developed to increase genital blood flow and provide a local therapeutic effect; completed Phase 1 PK/safety and progressed into Phase 2/Phase 2b clinical development.
Topical sildenafil cream (3.6%) — OTC candidate for erectile dysfunction (ED)
Topical cream formulation of sildenafil developed for local treatment of erectile dysfunction with the goal of low systemic exposure and potential OTC accessibility.
Topical ibuprofen cream (7.5%) — OTC candidate for localized pain
Topical ibuprofen cream formulated to deliver therapeutic analgesic levels to inflamed tissue while maintaining low systemic plasma concentrations; completed Phase 1 PK/safety and Phase 2 trials.
Services
Business development and licensing of patented topical formulation programs to commercial partners post-Phase 2 proof-of-concept.
Business development and licensing of patented topical formulation programs to commercial partners post-Phase 2 proof-of-concept.
Expertise Areas
- Clinical trial management (Phase 1–Phase 2b)
- Topical formulation development
- Transdermal/topical drug delivery science
- Regulatory strategy (FDA 505(b)(2) and agency engagement)
Key Technologies
- Topical/transdermal drug delivery platform
- Topical cream formulation (API reformulation)
- Pharmacokinetic (PK) bioanalysis
- Thermography for pharmacodynamics
News & Updates
SST and Daré Bioscience, Inc. announced enrollment in a study evaluating thermography technology to assess the pharmacodynamics of Sildenafil Cream, 3.6%.
SST and Daré Bioscience entered into a license and collaboration agreement for Sildenafil Cream, 3.6%, aiming for potential FDA approval for FSAD.
SST and Daré Bioscience announced the start of a content validity study to support efficacy assessment in FSAD.
A randomized controlled trial evaluating the efficacy of Sildenafil Cream in women with FSAD.
Daré Bioscience published efficacy results of Sildenafil Cream in a leading medical journal.
Daré Bioscience presented positive findings from a Phase 2b RESPOND study of Sildenafil Cream.
SST and Daré Bioscience, Inc. announced enrollment in a study evaluating thermography technology to assess the pharmacodynamics of Sildenafil Cream, 3.6%.
SST and Daré Bioscience entered into a license and collaboration agreement for Sildenafil Cream, 3.6%, aiming for potential FDA approval for FSAD.
SST and Daré Bioscience announced the start of a content validity study to support efficacy assessment in FSAD.
A randomized controlled trial evaluating the efficacy of Sildenafil Cream in women with FSAD.
Daré Bioscience published efficacy results of Sildenafil Cream in a leading medical journal.
Daré Bioscience presented positive findings from a Phase 2b RESPOND study of Sildenafil Cream.